Maladie veineuse thromboembolique et cancer

Martinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost 112:255–263. Cushman, 2004, Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology, Am J Med, 117, 19, 10.1016/j.amjmed.2004.01.018 Carrier, 2008, Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?, Ann Intern Med, 149, 323, 10.7326/0003-4819-149-5-200809020-00007 Heit, 2000, 3rd: Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study, Arch Intern Med, 160, 809, 10.1001/archinte.160.6.809 Blom, 2005, Malignancies, prothrombotic mutations, and the risk of venous thrombosis, Jama, 293, 715, 10.1001/jama.293.6.715 Blom, 2006, Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study, J Thromb Haemost, 4, 529, 10.1111/j.1538-7836.2006.01804.x Chew, 2006, Incidence of venous thromboembolism and its effect on survival among patients with common cancers, Arch Intern Med, 166, 458, 10.1001/archinte.166.4.458 Ay, 2010, Prediction of venous thromboembolism in cancer patients, Blood, 116, 5377, 10.1182/blood-2010-02-270116 Blom, 2004, The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma, J Thromb Haemost, 2, 1760, 10.1111/j.1538-7836.2004.00928.x Timp, 2013, Epidemiology of cancer-associated venous thrombosis, Blood, 122, 1712, 10.1182/blood-2013-04-460121 Khorana, 2008, Development and validation of a predictive model for chemotherapy-associated thrombosis, Blood, 111, 4902, 10.1182/blood-2007-10-116327 Thaler, 2012, Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials, Thromb Haemost, 108, 1042, 10.1160/TH12-04-0241 Kahn, 2012, Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, e195S, 10.1378/chest.11-2296 Carrier, 2014, Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer, Am J Med, 127, 82, 10.1016/j.amjmed.2013.09.015 Gould, 2012, Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, e227S, 10.1378/chest.11-2297 Agnelli, 2009, Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study, Lancet Oncol, 10, 943, 10.1016/S1470-2045(09)70232-3 Agnelli, 2012, Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer, N Engl J Med, 366, 601, 10.1056/NEJMoa1108898 Verso, 2012, A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score, Intern Emerg Med, 7, 291, 10.1007/s11739-012-0784-y Maraveyas, 2012, Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer, Eur J Cancer, 48, 1283, 10.1016/j.ejca.2011.10.017 Pelzer, 2015, Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial, J Clin Oncol, 33, 2028, 10.1200/JCO.2014.55.1481 Haas, 2012, Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer, Clin Appl Thromb Hemost, 18, 159, 10.1177/1076029611433769 Prandoni, 2002, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, 100, 3484, 10.1182/blood-2002-01-0108 Lee, 2015, Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial, Jama, 314, 677, 10.1001/jama.2015.9243 Lee, 2003, Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, N Engl J Med, 349, 146, 10.1056/NEJMoa025313 Meyer, 2002, Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study, Arch Intern Med, 162, 1729, 10.1001/archinte.162.15.1729 Deitcher, 2006, Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period, Clin Appl Thromb Hemost, 12, 389, 10.1177/1076029606293692 Hull, 2006, Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer, Am J Med, 119, 1062, 10.1016/j.amjmed.2006.02.022 Posch, 2015, Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants, Thromb Res, 136, 582, 10.1016/j.thromres.2015.07.011 Lyman, 2014, Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014, J Clin Oncol, 33, 654, 10.1200/JCO.2014.59.7351 Farge, 2013, International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, J Thromb Haemost, 11, 56, 10.1111/jth.12070 Kearon, 2016, Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report, Chest, 149, 315, 10.1016/j.chest.2015.11.026 Ihaddadene, 2014, Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis, Thromb Res, 134, 93, 10.1016/j.thromres.2014.04.028 van der Hulle T, den Exter PL, van den Hoven P, van der Hoeven JJ, van der Meer FJ, Eikenboom J, et al. Cohort study on the management of cancer-associated venous thromboembolism aimed at the safety of stopping anticoagulant therapy in patients cured from cancer. Chest 2016. Francis, 2015, Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study, J Thromb Haemost, 13, 1028, 10.1111/jth.12923 van Es, 2014, Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood, 124, 1968, 10.1182/blood-2014-04-571232 Prins, 2014, Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials, Lancet Haematol, 1, e37, 10.1016/S2352-3026(14)70018-3 Kleinjan, 2014, Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study, Ann Intern Med, 160, 451, 10.7326/M13-2056 Delluc, 2015, Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients, Thromb Res, 135, 298, 10.1016/j.thromres.2014.11.020 Sahut D’Izarn, 2012, Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case-control study, J Thromb Haemost, 10, 2032, 10.1111/j.1538-7836.2012.04868.x van der Hulle, 2016, Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients, J Thromb Haemost, 14, 105, 10.1111/jth.13172 Carrier, 2015, Screening for Occult Cancer in Unprovoked Venous Thromboembolism, N Engl J Med, 373, 697, 10.1056/NEJMoa1506623 Robin, 2016, Limited screening with versus without (18) F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial, Lancet Oncol, 17, 193, 10.1016/S1470-2045(15)00480-5 Amirkhosravi, 2007, The role of tissue factor pathway inhibitor in tumor growth and metastasis, Semin Thromb Hemost, 33, 643, 10.1055/s-2007-991531 Kuderer, 2009, Impact of venous thromboembolism and anticoagulation on cancer and cancer survival, J Clin Oncol, 27, 4902, 10.1200/JCO.2009.22.4584 Ludwig, 2006, The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo, Thromb Haemost, 95, 535, 10.1160/TH05-07-0515